NYSE:CVM CEL-SCI (CVM) Stock Price, News & Analysis $0.21 +0.01 (+4.07%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About CEL-SCI Stock (NYSE:CVM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CEL-SCI alerts:Sign Up Key Stats Today's Range$0.18▼$0.2150-Day Range$0.20▼$0.5152-Week Range$0.18▼$2.39Volume912,817 shsAverage Volume946,424 shsMarket Capitalization$16.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Read More… Remove Ads Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address CVM Stock News HeadlinesCEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.comMarch 30, 2025 | americanbankingnews.comCEL-SCI publishes new data from Multikine studyMarch 26, 2025 | markets.businessinsider.comEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.April 4, 2025 | Colonial Metals (Ad)CEL-SCI Announces Closing of $2.5 Million OfferingMarch 18, 2025 | finance.yahoo.comCEL-SCI announces pricing of $2.56M common stock offeringMarch 18, 2025 | markets.businessinsider.comCEL-SCI Announces Pricing of $2.5 Million OfferingMarch 17, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...March 15, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...March 15, 2025 | businesswire.comSee More Headlines CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed this year? CEL-SCI's stock was trading at $0.3999 at the start of the year. Since then, CVM stock has decreased by 50.5% and is now trading at $0.1980. View the best growth stocks for 2025 here. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSE:CVM) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. When did CEL-SCI's stock split? CEL-SCI's stock reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CEL-SCI own? Based on aggregate information from My MarketBeat watchlists, some other companies that CEL-SCI investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Pfizer (PFE), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/15/2024Today4/04/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:CVM CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471Employees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-238.05% Return on Assets-104.65% Debt Debt-to-Equity Ratio0.66 Current Ratio1.07 Quick Ratio1.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book1.38Miscellaneous Outstanding Shares80,112,000Free Float64,673,000Market Cap$16.58 million OptionableOptionable Beta0.95 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSE:CVM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.